Insider buying last 90 days
No open-market insider purchases were filed for NBIX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NBIX insider filing, plotted on the chart in Gekko.Open NBIX in Gekko
NASDAQ: NBIX
Neurocrine Biosciences (NBIX) Stock Analysis & Forecast
Sep 28 close
$140.44+2.04 (+1.5%)
Gekko Brief
AI summaryThis week brings a leadership update, with Neurocrine Biosciences appointing Eiry W. Roberts, M.D., alongside continued discussion of INGREZZA's sales trajectory, which grew 17% in the first half of 2026. Commentary from a Morgan Stanley discussion touched on AI, China and pipeline strategy as the company looks to diversify beyond INGREZZA ahead of a 2029 price consideration. Separately, positive Phase 4 KINECT-PRO data for INGREZZA in tardive dyskinesia was highlighted alongside raised full-year guidance, while RBC trimmed its price target on the stock to $187 from $198 while maintaining an Outperform rating.
NBIX closed at $140.44, up 1.5%, sitting between its 50-day average of $158.35 and 200-day average of $147.54, with the one-month return at -9.9% and the three-month return at -17.4%, against a 52-week range of $122.14 to $186.12. The GekkoIndex reads 72.1, placing the stock in the Buying zone. The price sits 38.6% below Gekko Fair Value of $228.69.
Over the next 20 trading days, the next earnings date falls on 27 October 2026, inside that window, following a July quarter in which reported EPS of $2.36 beat the $1.88 estimate yet the stock reacted -7.7%, with an average absolute reaction of 8.8% across recent quarters. Analyst coverage stands at 23 buy, 3 hold and 0 sell ratings among 26 firms, with a consensus target of $208.4. Seasonally, this calendar stretch has averaged a 2.9% return over 5 years, rising in 4 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Neurocrine Biosciences price vs fair value
Close $140.44200-day averageGekko Fair Value $228.69
Neurocrine Biosciences quick facts
- Market cap
- $14.12B
- P/E ratio
- 20.4
- Forward P/E
- 14.1
- EPS, TTM
- $6.81
- Revenue, TTM
- $3.37B
- Profit margin
- 20.9%
- Dividend yield
- —
- Beta
- 0.38
- Volume
- 1.42M avg 1.20M
- 1-year return
- −0.3%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6%
- 50-day average
- $158.35
- 200-day average
- $147.54
- Next earnings
- Oct 27
- Shares outstanding
- 101.6M
Neurocrine Biosciences swing-trade checklist
Neurocrine Biosciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $140.44 sits between the 50-day ($158.35) and 200-day ($147.54) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
72.1, Buying
Reading 72.1 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
38.6% below
Price is 38.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Oct 27, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.9% on average
From this point in the calendar, the next 20 trading days averaged +2.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Neurocrine Biosciences stock chart and price history
Neurocrine Biosciences closed at $140.44 on Sep 28, 2026, −0.3% over the past year, inside a 52-week range of $122.14 to $186.12.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.9%
- 3 months
- −17.4%
- 6 months
- +9.4%
- 1 year
- −0.3%
The full NBIX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NBIX in Gekko
Follow Neurocrine Biosciences through every session
Put NBIX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NBIX in GekkoFree for 7 days. No credit card required.
About Neurocrine Biosciences
Neurocrine Biosciences develops and sells medicines aimed at neurological, endocrine, and psychiatric disorders. Its best-known product is INGREZZA, a treatment for tardive dyskinesia, and the company also markets ONGENTYS for use alongside levodopa therapy in Parkinson's disease, ORILISSA for pain tied to endometriosis, and ORIAHNN, a non-surgical oral option for heavy menstrual bleeding caused by uterine fibroids.
Beyond its marketed treatments, the company runs a pipeline of experimental compounds addressing conditions such as focal epilepsy, rare pediatric epilepsy, essential tremor, major depressive disorder, anhedonia linked to depression, and schizophrenia. It pursues some of this work through licensing and collaboration agreements with other pharmaceutical and biotech organizations, including Heptares Therapeutics, Takeda, Idorsia, Xenon Pharmaceuticals, Voyager Therapeutics, BIAL Portela, Mitsubishi Tanabe Pharma, and AbbVie.
Neurocrine Biosciences was established in 1992 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker NBIX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- neurocrine.com
Neurocrine Biosciences GekkoIndex: the smart money zone
Neurocrine Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.1, in the Buying zone, down 1.2 points over five sessions.
72.1Buying
Down 1.2 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 26 | +0.8% | +1.8% |
| Accumulation | 224 | +0.2% | +1.6% |
| Neutral | 387 | +0.1% | +0.3% |
| Distribution | 24 | −0.9% | +0.4% |
| Selling | 11 | +1.7% | −4.0% |
Average NBIX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the NBIX price, zone by zone.Track NBIX in Gekko
Is Neurocrine Biosciences stock overvalued? Gekko Fair Value
Neurocrine Biosciences trades 38.6% below Gekko Fair Value of $228.69, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Neurocrine Biosciences shares are worth, recalculated every trading day.
$228.69
Gekko Fair Value, Sep 26, 2026
38.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open NBIX in Gekko
Neurocrine Biosciences insider and Congress trading
No open-market insider purchases were filed for Neurocrine Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NBIX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NBIX, plotted on the chart in Gekko.Open NBIX in Gekko
Buybacks
Neurocrine Biosciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $12.00M
- As a share of market cap
- 0.08%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold NBIX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Neurocrine Biosciences earnings: next date and track record
Neurocrine Biosciences reports on Oct 27, 2026 (28 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Oct 27, 2026
28 days away
- EPS estimate
- $2.59
- Revenue estimate
- $1.04B
5 of 8reports beat the EPS estimate
±8.8%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Neurocrine reported a strong Q2 2026 driven by record commercial performance across its three marketed medicines (INGREZZA, CRENESSITY, VYKAT XR). Total revenue exceeded $950M (pro forma ~$998M including full-quarter VYKAT XR), with INGREZZA net sales of $716M (+15% YoY) and CRENESSITY sales of $184M. Management highlighted sustained new patient starts, growing prescriber adoption for CRENESSITY (estimated ~15% penetration of diagnosed population), and steady early launch trends for VYKAT XR following the May acquisition. The company raised INGREZZA full-year guidance to $2.825B–$2.875B and reported non-GAAP EPS of $2.85 for the quarter. Management emphasized continued investment in R&D, multiple Phase 3 readouts expected in H2 2027 (osavampator in MDD and dereclidine in schizophrenia), ongoing pipeline progress across muscarinic and obesity programs, and planned integration of the Soleno/VYKAT XR franchise. Clinical data presented (ENDO 2026) reinforced CRENESSITY and VYKAT XR long-term benefits. Management expressed confidence in commercialization, integration, and strategic fit but acknowledged routine integration and payer/pricing discussions ahead (including IRA/MFP implications for 2029).
- Guidance
- INGREZZA full-year 2026 guidance raised to $2.825 billion to $2.875 billion (midpoint ≈ 13% YoY growth). Pro forma Q2 revenues including full-quarter VYKAT XR: ~$998 million. Non-GAAP EPS for Q2: $2.85 per share. No other explicit numeric FY revenue or EPS guidance provided on the call.
- Risks flagged
- Potential 2029 IRA/MFP pricing and access impact (discussions ongoing); payer/pricing dynamics and potential contracting costs; integration risk and short-term sales variability for VYKAT XR (discontinuations and market education/titration challenges); competitive dynamics in VMAT2 and CAH spaces; clinical and readout risk for Phase 3 assets (osavampator, dereclidine); ex-US regulatory/launch uncertainties (e.g., withdrawn EMA filing for VYKAT XR during close); and standard execution / macro risks noted in SEC filings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $2.36 est $1.88 | $959.0M est $891.2M | −7.7% |
| May 5, 2026 | $1.94 est $1.70 | $814.5M est $768.3M | +9.7% |
| Feb 11, 2026 | $1.88 est $1.80 | $805.5M est $790.5M | −10.6% |
| Oct 28, 2025 | $2.17 est $2.07 | $794.9M est $806.8M | −7.3% |
| Jul 30, 2025 | $1.06 est $0.98 | $687.5M est $746.4M | −4.4% |
| May 5, 2025 | $0.08 est $0.54 | $572.6M est $559.6M | +8.4% |
| Feb 6, 2025 | $1.69 est $1.93 | $627.7M est $629.4M | −18.9% |
| Oct 30, 2024 | $1.81 est $1.82 | $622.1M est $600.6M | +3.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Neurocrine Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Neurocrine Biosciences is $208.40, +48.4% from the last close, from 26 firms rating the stock in the last 90 days.
$208.40consensus 12-month target, +48.4% from the last close
Now $140.44Avg $208.40
Low $165High $253
Each firm’s latest rating in the last 90 days: 26 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Bernstein | $218 | +55.2% |
| Sep 18 | CCB Intl. | $188 | +33.9% |
| Sep 14 | RBC Capital | $198 | +41.0% |
| Sep 11 | Morgan Stanley | $183 | +30.3% |
| Sep 8 | RBC Capital | $198 | +41.0% |
+1.8%average 20-day move after past Buying readings
+2.9%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Neurocrine Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Neurocrine Biosciences averaged +2.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 2 of 5 |
| Next 10 trading days | +1.8% | 2 of 5 |
| Next 15 trading days | +4.3% | 3 of 5 |
| Next 20 trading days | +2.9% | 4 of 5 |
| Next 30 trading days | +7.5% | 4 of 5 |
For scale, NBIX’s typical 20-trading-day move in either direction is about 6%.
Neurocrine Biosciences market cap and key statistics
Neurocrine Biosciences’s market cap is $14.12B, with a P/E ratio of 20.4 and revenue of $3.37B over the last twelve months.
Valuation
- Market cap
- $14.12B
- P/E ratio
- 20.4
- Forward P/E
- 14.1
- EPS, TTM
- $6.81
- Gekko Fair Value
- $228.69
Trading
- Volume
- 1.42M
- Avg volume, 20 days
- 1.20M
- 52-week high
- $186.12
- 52-week low
- $122.14
- Shares outstanding
- 101.6M
Financials
- Revenue, TTM
- $3.37B
- Profit margin
- 20.9%
- Return on equity
- 22.1%
- Quarterly earnings growth, YoY
- +31.1%
Risk and income
- Beta
- 0.38
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6%
Neurocrine Biosciences stock news this week
Coverage of Neurocrine Biosciences this week reads neutral: 1 positive, 3 neutral and 1 negative headlines.
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.PRNewsWire, Sep 28
- Neurocrine Biosciences, Inc. (NBIX) Stock ForecastsYahoo! Finance Canada, Sep 24
- Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?Eastern Progress, Sep 23
- Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and BallEastern Progress, Sep 23
- Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price HitMarketBeat, Sep 23
- RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Ratingmarketscreener.com, Sep 21
Neurocrine Biosciences peers
Neurocrine Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Neurocrine Biosciences stock FAQ
What is Neurocrine Biosciences’s market cap?
Neurocrine Biosciences’s market cap is $14.12B at the Sep 28, 2026 close of $140.44, with 101.6M shares outstanding. The shares trade on a P/E ratio of 20.4.
What is the Neurocrine Biosciences stock forecast?
The consensus analyst 12-month price target for Neurocrine Biosciences is $208.40, +48.4% from the last close. Of the 26 firms that rated the stock in the last 90 days, 23 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Neurocrine Biosciences stock overvalued or undervalued?
On Gekko’s estimate Neurocrine Biosciences is undervalued: the Sep 28, 2026 close of $140.44 is 38.6% below Gekko Fair Value of $228.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Neurocrine Biosciences report earnings next?
Neurocrine Biosciences is expected to report on Oct 27, 2026 (28 days away). Analysts expect earnings of $2.59 per share on revenue of $1.04B. Neurocrine Biosciences beat the earnings estimate in 5 of its last 8 reports, moving 8.8% on average across the report.
What is Neurocrine Biosciences’s 52-week high and low?
Neurocrine Biosciences’s 52-week high is $186.12 and its 52-week low is $122.14; it closed at $140.44 on Sep 28, 2026, −0.3% over the past year.
Is Neurocrine Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Neurocrine Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.